EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Hydrophilic Intraocular Lens Opacification Following Repeated Intravitreal Bevacizumab Injections: A Case Report

Miljana Smiljic

Case Reports in Ophthalmology · 2026-11-09

DOI: 10.1159/cop/acaag040 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background: Opacification of hydrophilic intraocular lenses (IOLs) is a rare but visually significant complication, most commonly associated with calcium phosphate deposition. Increasing evidence suggests a possible association with repeated intraocular procedures, including intravitreal anti-VEGF therapy. Case presentation: A female patient, aged 74 years at presentation with IOL opacification, had undergone cataract surgery because of decreased visual acuity. Phacoemulsification with implantation of a hydrophilic IOL was performed in the left eye without documented intraoperative complications. Postoperative optical coherence tomography (OCT) demonstrated exudative age-related macular degeneration (AMD). Several months after cataract surgery, intravitreal bevacizumab therapy was initiated, administered every three weeks in alternating eyes (six injections in the right eye and seven in the left eye). In February 2024, approximately 13 months after cataract surgery, the patient presented with progressive visual decline in the left eye. Slit-lamp examination revealed diffuse left IOL opacification. Nd:YAG capsulotomy was performed without visual improvement. IOL explantation and secondary implantation were subsequently performed, resulting in improvement of BCVA in the left eye to 0.6–0.7. Conclusion: This case supports a potential association between repeated intravitreal anti-VEGF injections and hydrophilic IOL opacification. The choice of IOL material may be an important consideration in patients requiring long-term intravitreal therapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →